Cartilage storage solution for chondrocyte viability and biomaterial preservation

Information

  • Research Project
  • 8447752
  • ApplicationId
    8447752
  • Core Project Number
    R43AR064033
  • Full Project Number
    1R43AR064033-01
  • Serial Number
    064033
  • FOA Number
    PA-12-088
  • Sub Project Id
  • Project Start Date
    5/27/2013 - 11 years ago
  • Project End Date
    8/26/2014 - 9 years ago
  • Program Officer Name
    WANG, XIBIN
  • Budget Start Date
    5/27/2013 - 11 years ago
  • Budget End Date
    8/26/2014 - 9 years ago
  • Fiscal Year
    2013
  • Support Year
    01
  • Suffix
  • Award Notice Date
    5/23/2013 - 11 years ago

Cartilage storage solution for chondrocyte viability and biomaterial preservation

DESCRIPTION (provided by applicant): Resurfacing of articular cartilage with cold stored osteochondral allografts is employed clinically for repair of trauma and osteoarthritis-induced articular cartilage surface damage. Chondrocyte viability of transplanted articular cartilage is accepted as one of the determinants of outcome following osteochondral allograft transplantation. Refrigerated storage methods used for cartilage storage prior to clinical cartilage utilization need to be carefully evaluated because the tissue may be experiencing clinically significant deterioration during storage. We have recently investigated cartilage cell viability and matrix permeability during storage in culture medium, as well as storage solutions, and found that both deteriorate within the time frames that they are utilized for clinical procedures. Culture medium that preserves chondrocyte viability best under cold refrigerated storage conditions does not preserve matrix permeability and, vice versa, nutritionally deficient solutions that preserve matrix permeability have significantly less cell viability. This objective ill be developed in three specific aims. In these aims two solution formulations, one based on intracellular and the other on extracellular milieu designs will be investigated. Chondrocyte viability, chemistry, biomaterial properties and gene expression will be compared over time during porcine cartilage storage. The gene expression studies will determine which formulation maintains normal untreated cartilage expression of Sox9, aggrecan, collagen type II (versus dedifferentiation marker collagen type I), cartilage oligomeric matrix, a matrix resorption marker plus protein and hypertrophic marker genes. The solution that provides the longest preservation of chondrocytes with a normal untreated chondrocyte phenotype with minimal if any cartilage biomaterial changes will be selected for further investigation in vivo and translation to human cartilage in a subsequent Phase II SBIR application.

IC Name
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
  • Activity
    R43
  • Administering IC
    AR
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    312642
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    846
  • Ed Inst. Type
  • Funding ICs
    NIAMS:312642\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CELL AND TISSUE SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
    175100333
  • Organization City
    NORTH CHARLESTON
  • Organization State
    SC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    294064931
  • Organization District
    UNITED STATES